In vitro development and optimization of cell-laden injectable bioprinted gelatin methacryloyl (GelMA) microgels mineralized on the nanoscale.

Bioprinting Bone tissue engineering GelMA Microgels Mineralization Osteocytes Sclerostin

Journal

Biomaterials advances
ISSN: 2772-9508
Titre abrégé: Biomater Adv
Pays: Netherlands
ID NLM: 9918383886206676

Informations de publication

Date de publication:
02 Mar 2024
Historique:
received: 11 10 2023
revised: 21 02 2024
accepted: 22 02 2024
medline: 9 3 2024
pubmed: 9 3 2024
entrez: 8 3 2024
Statut: aheadofprint

Résumé

Bone defects may occur in different sizes and shapes due to trauma, infections, and cancer resection. Autografts are still considered the primary treatment choice for bone regeneration. However, they are hard to source and often create donor-site morbidity. Injectable microgels have attracted much attention in tissue engineering and regenerative medicine due to their ability to replace inert implants with a minimally invasive delivery. Here, we developed novel cell-laden bioprinted gelatin methacrylate (GelMA) injectable microgels, with controllable shapes and sizes that can be controllably mineralized on the nanoscale, while stimulating the response of cells embedded within the matrix. The injectable microgels were mineralized using a calcium and phosphate-rich medium that resulted in nanoscale crystalline hydroxyapatite deposition and increased stiffness within the crosslinked matrix of bioprinted GelMA microparticles. Next, we studied the effect of mineralization in osteocytes, a key bone homeostasis regulator. Viability stains showed that osteocytes were maintained at 98 % viability after mineralization with elevated expression of sclerostin in mineralized compared to non-mineralized microgels, showing that mineralization can effectively enhances osteocyte maturation. Based on our findings, bioprinted mineralized GelMA microgels appear to be an efficient material to approximate the bone microarchitecture and composition with desirable control of sample injectability and polymerization. These bone-like bioprinted mineralized biomaterials are exciting platforms for potential minimally invasive translational methods in bone regenerative therapies.

Identifiants

pubmed: 38457904
pii: S2772-9508(24)00048-7
doi: 10.1016/j.bioadv.2024.213805
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

213805

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mauricio Gonçalves da Costa Sousa (MG)

Knight Cancer Precision Biofabrication Hub, Cancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, Oregon Health & Science University, United States of America; Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, United States of America.

Gabriela de Souza Balbinot (G)

Universidade Federal do Rio Grande do Sul - UFRGS, School of Dentistry, Dental Materials Department, Porto Alegre, RS, Brazil.

Ramesh Subbiah (R)

Knight Cancer Precision Biofabrication Hub, Cancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, Oregon Health & Science University, United States of America; Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, United States of America.

Rahul Madathiparambil Visalakshan (RM)

Knight Cancer Precision Biofabrication Hub, Cancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, Oregon Health & Science University, United States of America; Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, United States of America.

Anthony Tahayeri (A)

Knight Cancer Precision Biofabrication Hub, Cancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, Oregon Health & Science University, United States of America; Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, United States of America.

Maria Elisa Lima Verde (MEL)

Knight Cancer Precision Biofabrication Hub, Cancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, Oregon Health & Science University, United States of America; Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, United States of America.

Avathamsa Athirasala (A)

Knight Cancer Precision Biofabrication Hub, Cancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, Oregon Health & Science University, United States of America; Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, United States of America.

Genevieve Romanowicz (G)

Knight Campus for Accelerating Scientific Impact, University of Oregon, United States of America.

Robert E Guldberg (RE)

Knight Campus for Accelerating Scientific Impact, University of Oregon, United States of America.

Luiz E Bertassoni (LE)

Knight Cancer Precision Biofabrication Hub, Cancer Early Detection Advanced Research (CEDAR), Knight Cancer Institute, Oregon Health & Science University, United States of America; Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, United States of America; Center for Regenerative Medicine, School of Medicine, Oregon Health & Science University, United States of America; Department of Biomedical Engineering, School of Medicine Oregon Health & Science University, United States of America; Department of Oral Rehabilitation and Biosciences, School of Dentistry, Oregon Health & Science University, United States of America. Electronic address: bertasso@ohsu.edu.

Classifications MeSH